Great post Seel. Quick Q : How big of a role do you think tumor mapping at DF will play in helping with future trial strategy and participant selection going forward? In my mind this is another valuable tool that many trials do not yet fully utilize (correct me if I am wrong).

Seems to me this gives us a big strategic advantage and even more better and refined data that will help maximize the efficacy seen in future participants.Dr Menon spoke about this in the PR a few weeks back:

"Dana-Farber’s extensive tumor mapping technologies will help us pinpoint which patients will benefit the most from Kevetrin as we move towards defining the Maximum Tolerated Dose."

Between tumor mapping and the use of biomarkers, I believe we will have a wealth of extensive data across each patient to see who is responding best to treatment, and where the most robust anti-tumor activity is taking place. Valuable assets for planning future trials.

Appreciate your thoughts on this, thanks Seel!